Metagenomi, Inc. (MGX) — SEC Filings
Metagenomi, Inc. (MGX) — 23 SEC filings. Latest: 8-K (Nov 12, 2025). Includes 9 8-K, 5 10-Q, 3 S-1/A.
View Metagenomi, Inc. on SEC EDGAR
Overview
Metagenomi, Inc. (MGX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 12, 2025: Metagenomi, Inc. filed an 8-K on November 12, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits as of November 11, 2025. The filing details the company's operational and financial status, with no specific dollar amou
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 1 bearish, 21 neutral, 1 mixed. The dominant filing sentiment for Metagenomi, Inc. is neutral.
Filing Type Overview
Metagenomi, Inc. (MGX) has filed 9 8-K, 5 10-Q, 1 DEF 14A, 2 10-K, 2 SC 13G, 3 S-1/A, 1 S-1 with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of MGX's 20 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $12.64M |
| Net Income | -$44.95M |
| Cash Position | $26.85M |
| Total Assets | $272.28M |
Key Executives
- Dr. Brian Atwood
- Dr. Sarah E. Michaels
- Brian C. Thomas, Ph.D.
- Mitchell S. Bloom
- Edwin M. O'Connor
- Justin S. Platt
Industry Context
Metagenomi operates in the rapidly evolving biotechnology sector, focusing on gene editing and therapeutic development. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success often depends on technological innovation, strategic partnerships, and the ability to secure substantial funding.
Top Tags
sec-filing (4) · Biotechnology (4) · 10-Q (4) · Metagenomi (4) · IPO (4) · 8-k (3) · Registration Statement (3) · corporate-governance (2) · biotechnology (2) · financials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Collaboration Revenue | $12.64M | 59.4% decrease from $31.17M in prior year for six months ended June 30, 2025 |
| Net Loss | $44.95M | Widened from $35.89M in prior year for six months ended June 30, 2025 |
| Research and Development Expenses | $47.65M | Decreased 20.3% from $59.76M in prior year for six months ended June 30, 2025 |
| Total Assets | $272.28M | Decreased from $324.60M at December 31, 2024, to June 30, 2025 |
| Cash and Cash Equivalents | $26.85M | Slight decrease from $27.39M at December 31, 2024, to June 30, 2025 |
| Available-for-Sale Marketable Securities | $178.14M | Dropped from $220.92M at December 31, 2024, to June 30, 2025 |
| Change in Fair Value of Long-Term Investments | $1.29M | Loss incurred for six months ended June 30, 2025 |
| Common Shares Outstanding | 37,533,136 | As of August 5, 2025 |
| Reporting Period End Date | 2025-03-31 | Covers the first quarter of 2025 |
| Start of Reporting Period | 2025-01-01 | Beginning of the first quarter of 2025 |
| Valuation Technique | 0.5724 | Indicates a specific valuation method used, likely for financial instruments. |
| Filing Date | 20240814 | The date the 10-Q was officially submitted to the SEC. |
| Prior Period End Date | 2023-12-31 | Reference date for financial instruments |
| Date of Name Change | 2019-08-12 | Metagenomi, Inc. was formerly Metagenomi Technologies, LLC |
| Agreement Start Date | 2027-01-01 | Collaboration and License Agreement with Ionis |
Frequently Asked Questions
What are the latest SEC filings for Metagenomi, Inc. (MGX)?
Metagenomi, Inc. has 23 recent SEC filings from Jan 2024 to Nov 2025, including 9 8-K, 5 10-Q, 3 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MGX filings?
Across 23 filings, the sentiment breakdown is: 1 bearish, 21 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Metagenomi, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Metagenomi, Inc. (MGX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Metagenomi, Inc.?
Key financial highlights from Metagenomi, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MGX?
The investment thesis for MGX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Metagenomi, Inc.?
Key executives identified across Metagenomi, Inc.'s filings include Dr. Brian Atwood, Dr. Sarah E. Michaels, Brian C. Thomas, Ph.D., Mitchell S. Bloom, Edwin M. O'Connor and 1 others.
What are the main risk factors for Metagenomi, Inc. stock?
Of MGX's 20 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Metagenomi, Inc.?
Forward guidance and predictions for Metagenomi, Inc. are extracted from SEC filings as they are enriched.